Your Account
Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy
Molecular Mechanisms and Clinical Applications
(To see other currencies, click on price)
Add to basket  


Main description:

Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital – Azienda Sanitaria Locale 21 of the Veneto Region – and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.


The papers in this volume have been presented at the X International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy held in Verona, Italy, from November 30th to December 3rd 2007.

Back cover:

The platinum-containing chemotherapeutic agents remain key components of many of the most effective regimens for the treatment of cancer. New information about the chemistry, pharmacology and molecular mechanisms by which these drugs work is leading to both the development of new drugs and more effective use of existing members of this class. Better definition of the genetic basis of malignancies is offering intriguing new insights in to how to use these drugs in a more individualized manner. "Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications", edited by Andrea Bonetti, Steve B. Howell, Roberto Leone, and Franco Muggia, provides succinct summaries of the major new developments in field of platinum drug therapy drawn from presentations made at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy that took place in Verona, Italy, in December 2007. This meeting, held once every 4 years, brought together the world’s leading investigators working on platinum drugs and their contributions provide a detailed survey of the major research directions in this rapidly evolving field.


Platinum chemotherapy: an oncologic success story Lawerence H. Einhorn Platinum compounds in clinical development Hilary Calvert Satraplatin: overview Cristiana Sessa Satraplatin in prostate cancer Cora Sternberg New formulations Roman Perez-Soler Novel drug delivery systems: AP5346 Stephen B. Howell CTR1 as a determinant of platinum drug transport Stephen B. Howell ATP7B regulates intracellular sequestration of Pt drugs Rouhi Safaei Molecular alterations of oxaliplatin-resistant cell exhibiting accumulation defects Paola Perego How to overcome cisplatin resistance through proton pump inhibitors Stefano Fais Multiple mechanisms of resistance to cisplatin in cancer cells Michael Gottsman Platinum drug damage to DNA and nucleosomes: recognition/repair and cell-response mechanisms Stephen J. Lippard Molecular rationale to improve platinum selectivity Maurizio D’Incalci Recognition and processing of platinum drugs-DNA adducts Stephen G. Chaney Platinum drugs and DNA repair: lessons from the NCI-60 panel and clinical correlates Jacques Robert Effects of platinated compounds in signal transduction: role of interaction with other drugs Godefridus J. Peters Platinum drugs as radio-sensitizer Silvia Formenti Head and Neck cancer Lisa Licitra Non-colorectal cancer Florian Lordick Colorectal cancer Andrea Bonetti New drugs for the management of chemotherapy-induced nausea and vomiting Matti Aapro Breast cancer Luca Gianni Ovarian cancer Franco Muggia Cancer of the uterus Paul Hoskins Lung cancer Giuseppe Giaccone Heavy metal compounds in cancer chemotherapy: positive findings Gianni Sava, Heavy metal compounds in cancer chemotherapy: negative findings Jan Schellens Neurotoxicity Guido Cavalletti Anemia and myelosuppression Fabio Benedetti Platinum drugs and the children with cancer Riccardo Riccardi Allergic reactions Eleni Andreopoulou Optimizing dose using patient characteristics Etienne Chatelut The real impact of intraperitoneal chemotherapy in ovarian cancer Franco Muggia IP Therapy - Where do we go from here Stephen B Howell


ISBN-13: 9781603274586
Publisher: Springer (Humana Press)
Publication date: December, 2008
Pages: 416
Availability: Available
Subcategories: Oncology, Pharmacology
Related books
From the same series


Average Rating